Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study

Table 3 Cox regression analysis results considering the 3-month interval and a relative LV GLS decrease of > 12%

Variable	B	SE	HR	95% CI		P
Variable	B	SE	HR	Inferior	Superior	P
Univariate analysis
Age ≥ 60 years	− 1.322	0.556	0.267	0.090	0.793	0.018^a
BMI ≥ 25 mg/m²	0.434	0.658	1.543	0.425	5.606	0.51
Doxorubicin ≥250 mg/m²	0.105	1.041	1.111	0.144	8.545	0.92
Trastuzumab	−0.108	0.556	0.898	0.302	2.672	0.85
HTN	−1.306	0.570	0.271	0.089	0.828	0.022^a
DM	−0.114	0.769	0.892	0.198	4.024	0.88
DLP	−0.114	0.769	0.892	0.198	4.024	0.88
Smoking	−1.483	1.016	0.238	0.032	1.738	0.16
Multivariate analysis
Age ≥ 60 years	0.732	0.713	2.080	0.514	8.418	0.31
HTN	0.883	0.731	2.4119	0.577	10.132	0.23

B coefficient, BMI body mass index, CI confidence interval, DLP dyslipidemia, DM diabetes mellitus, HR hazard ratio, HTN hypertension, LV GLS left ventricular global longitudinal strain, SE standard error
^aP < 0.05

ISSN: 2057-3804